Abstract: The invention relates to a packaging, preferably for foodstuffs, said packaging comprising a container and a lid, both of which is made of a material which is suitable for injection moulding, said lid being sealable relative to the container; and wherein the lid comprises an elevated portion for abutment on the internal, upper edge of the container, wherein at least a portion of the lid (2) is made with a sealing zone (7, 8) for joining with the container (1), said sealing zone (7, 8) being added with an active material which, by influence during joining, changes the material in the sealing zone (7, 8) to the effect that the sealing becomes weaker than the surrounding material, whereby the scaling is, upon opening, broken in the joint and not in the surrounding material.

Abstract: The packaging (1) comprises a container (2) and a lid (3) that can be sealed to the container (2). An edge (4) of the lid (3) is provided with a pull tab (5) facilitating the removal of the lid (3) from the container (2). The lid (3) and pull tab (5) are injection moulded integrally, and the pull tab (5) has the form of a flexible grid-like flap that is bendable to a substantially upright position. The pull tab (5) is formed by a number of spaced, parallel and interconnected bars (7) that extend in a direction substantially at right angles to the direction of pulling of the pull tab (5).

Abstract: The invention relates to a packaging, preferably for foodstuffs, said packaging comprising a container and a lid, both of which is made of a material which is suitable for injection moulding, said lid being sealable relative to the container; and wherein the lid comprises an elevated portion for abutment on the internal, upper edge of the container, wherein at least a portion of the lid (2) is made with a sealing zone (7, 8) for joining with the container (1), said sealing zone (7, 8) being added with an active material which, by influence during joining, changes the material in the sealing zone (7, 8) to the effect that the sealing becomes weaker than the surrounding material, whereby the scaling is, upon opening, broken in the joint and not in the surrounding material.

Abstract: The present invention provides pharmaceutical compositions comprising as an active ingredient candesartan or candesartan cilexetil, compositions exhibiting a relative bioavailability, measured as area under the curve, of more than 1.5.

Abstract: An oral pharmaceutical formulation comprising an inhibitor compound of the ileal bile acid transport (IBAT inhibitor), an HMG Co-A reductase inhibitor and a therapeutically acceptable carrier characterised in that the formulation is designed to deliver the IBAT inhibitor in the ileum and the HMG Co A reductase inhibitor non-specifically into the GI tract. The IBAT inhibitor compound and the HMG Co-A reductase inhibitor can also be administered in combination with a bile acid binder to alleviate possible side effects of therapy with IBAT inhibitor compounds, such as for instance diarrhoea. The bile acid binder may be formulated for colon release.